Melio

Melio is developing a rapid, culture-free bloodborne pathogen testing platform integrating proprietary assays, microfluidics, and machine-learning. The company targets faster and more accurate infectious disease diagnoses, aiming to reduce antimicrobial misuse and address antibiotic resistance. The platform is designed for comprehensive, direct-from-blood detection of a broad spectrum of pathogens, with a focus on real-time adaptability to new and emerging threats. Melio's system is in development and not yet commercialized.